Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Investor Presentation (March 2016)
20 slides from Ani Pharmaceuticals's investor presentation, Mar 9, 2016
Slide 1: Corporate Presentation March 2016
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation March 2016
Slide 2: Forward-Looking Statements
Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statem
Slide 3: ANI Mission Statement
3 ANI Mission Statement ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances, anti - cancer (oncolytics
Slide 4: ANI Overview – Positioned for Growth
ANI Overview – Positioned for Growth ANI Today ▪ Current business – For the year ended December 31, 2015: $76.3 million total net revenues □ $55.2 million Generic Rx product revenues □ $11.0 million Brand Rx product revenues □ $10.1 million c ontract manufacturing/services revenues □ Growth of 36% y
Slide 5: ANI Acquisition Highlights
5 ANI Acquisition Highlights 2013 Completed merger with BioSante Pharmaceuticals and obtains NASDAQ Global Market listing (NASDAQ: ANIP), June 2013 2014 Acquired 31 previously marketed generic products from Teva for $12.5 million and a percentage of future gross profits, January 2014 2014 Acquired L
Slide 6: Sales and Marketing Overview
6 Sales and Marketing Overview
Slide 7: ANI Revenue Growth
ANI Revenue Growth 7 $s in millions 39% C ost of sales as a percentage of net revenues, excluding depreciation and amortization 42% 43% 33% 21% 20%
Slide 8: ANI Generic Rx Product Portfolio
ANI Generic Rx Product Portfolio Generic Products Market Share (1) Competitors (2) EE/MT Tablets 50% 3 Fluvoxamine Tablets 56% 3 HC Enema 90% 2 Metoclopramide Solution 26% 2 Opium Tincture 70% 3 Methazolamide Tablets 29% 3 Etodolac Capsules 21% 3 Propafenone Tablets 5% 4 Oxycodone Solution Launched
Slide 9: ANI Brand Rx Product Portfolio
ANI Brand Rx Product Portfolio 9 Lithobid ® Tablets Bipolar Disorder Vancocin ® Capsules C. difficile - Associated Diarrhea Cortenema ® U lcerative Colitis Reglan ® Gastroesophageal Reflux 2015 Net Sales: $11.0M
Slide 10: ANI Contract Manufacturing and Other Current Business
ANI Contract Manufacturing and Other 10 Current Business ▪ Four customers – Seven products and seventeen SKUs – Contract manufacturing and contract packaging 2015 Net Sales: $10.1M
Slide 11: Business Development / Product Development Overview
11 Business Development / Product Development Overview
Slide 12: Business Development Activity
Business Development Activity 12 $1.1 $0.1 G e n e r i c s DONEPEZIL (Partnership with Dexcel) FDF Partnership Private P TEVA ANDA BASKET 2 (22 previously approved ANDAs) TEVA ANDA BASKET 1 (31 previously approved ANDAs) Total $152.2 FDF Partnership Private Acquisition Public P P P $25.0 P $12.5 Acq
Slide 13: ANI Product Development Pipeline
13 ANI Product Development Pipeline 85 p roducts in development, total combined current market: $4.5 billion (1) ▪ 57 products were acquired and of those, ANI believes 48 can be commercialized based on either a CBE - 30 or PAS ▪ ANI anticipates launching 12 products by the end of 2016: (1) Based on
Slide 14: Manufacturing Overview
a Manufacturing Overview Pormcewia ne
Slide 15: ANI Manufacturing – Main Street Facility
15 ANI Manufacturing – Main Street Facility Location: Baudette , Minnesota ▪ 52,000 square feet of manufacturing , packaging, and warehouse facilities ▪ Rx solutions , suspensions , topicals , tablets , and capsules ▪ DEA - licensed for Schedule II controlled substances ▪ 17,000 square feet of labor
Slide 16: ANI Manufacturing – IDC Road Facility
16 ANI Manufacturing – IDC Road Facility Location: Baudette, Minnesota ▪ Fully - contained h igh potency facility with capabilities to manufacture h ormone , steroid , and oncolytic products ▪ 47,000 square feet of manufacturing and packaging, and warehouse facilities ▪ 100 nano - gram per eight - h
Slide 17: ANI Summary
ANI Summary ANI is an integrated specialty generic pharmaceutical firm with: ▪ Profitable base business generating organic growth – 2016 Annual guidance (1) □ Net revenues of $105 million to $120 million □ Adjusted non - GAAP EBITDA of $45 million to $53 million □ Adjusted non - GAAP Net Income Per
Slide 18: Appendix A
a Appendix A Phormcenay ne
Slide 19: U.S. GAAP Reconciliations
U.S. GAAP Reconciliations 19 2015 2014 2015 2014 Operating Income $6,268 $10,772 $32,700 $20,006 Add back Depreciation and amortization 2,111 1,282 6,900 3,878 Add back Stock-based compensation 1,139 704 3,856 3,423 Adjusted non-GAAP EBITDA $9,518 $12,758 $43,456 $27,307 ANI Pharmaceuticals, Inc. an
Slide 20: U.S. GAAP Reconciliations
U.S. GAAP Reconciliations 20 2015 2014 2015 2014 Net Income 2,876$ 21,006 $ 15,375 $ 28,747 Add back Tax provision 625 (10,946) 6,358 (9,368) Depreciation and amortization expense 2,111 1,282 6,900 3,878 Non-cash interest expense 1,722 560 6,831 560 Stock-based compensation 1,139 704 3,856 3,423 Exc
ANI Pharmaceuticals — Investor Presentation (March 2016) on 6ix